10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

FBLN1 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP14671b

Specification

FBLN1 Antibody (C-term) - Product Information

Application	**WB, IHC-P,E**
Primary Accession	P23142
Other Accession	Q08879, NP_001987.2, NP_006477.2
Reactivity	**Human, Mouse**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit IgG**
Calculated MW	**77214**
Antigen Region	**622-650**

FBLN1 Antibody (C-term) - Additional Information

Gene ID 2192

Other Names
Fibulin-1, FIBL-1, FBLN1

Target/Specificity
This FBLN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 622-650 amino acids from the C-terminal region of human FBLN1.

Dilution
WB~~1:1000
IHC-P~~1:10~50

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
FBLN1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

FBLN1 Antibody (C-term) - Protein Information

Name FBLN1

Function Incorporated into fibronectin-containing matrix fibers. May play a role in cell adhesion

and migration along protein fibers within the extracellular matrix (ECM). Could be important for certain developmental processes and contribute to the supramolecular organization of ECM architecture, in particular to those of basement membranes. Has been implicated in a role in cellular transformation and tumor invasion, it appears to be a tumor suppressor. May play a role in haemostasis and thrombosis owing to its ability to bind fibrinogen and incorporate into clots. Could play a significant role in modulating the neurotrophic activities of APP, particularly soluble APP.

Cellular Location
Secreted, extracellular space, extracellular matrix


Tissue Location
Isoform A and isoform B are only expressed in placenta. Isoform C and isoform D are expressed in a variety of tissues and cultured cells.

FBLN1 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

FBLN1 Antibody (C-term) - Images




FBLN1 Antibody (C-term) (Cat. #AP14671b) western blot analysis in mouse cerebellum tissue lysates (35ug/lane).This demonstrates the FBLN1 antibody detected the FBLN1 protein (arrow).

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



FBLN1 Antibody (C-term) (Cat. #AP14671b) western blot analysis in human placenta tissue lysates (35ug/lane).This demonstrates the FBLN1 antibody detected the FBLN1 protein (arrow).



FBLN1 Antibody (C-term) (AP14671b)immunohistochemistry analysis in formalin fixed and paraffin embedded human placenta tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of FBLN1 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

FBLN1 Antibody (C-term) - Background

Fibulin 1 is a secreted glycoprotein that becomes incorporated into a fibrillar extracellular matrix. Calcium-binding is apparently required to mediate its binding to laminin and nidogen. It mediates platelet adhesion via binding fibrinogen. Four splice variants which differ in the 3' end have been identified. Each variant encodes a different isoform, but no functional distinctions have been identified among the four variants.

FBLN1 Antibody (C-term) - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Li, C., et al. Mol. Vis. 16, 689-697 (2010) :
Wooten, E.C., et al. PLoS ONE 5 (1), E8830 (2010) :
Argraves, W.S., et al. Histochem. Cell Biol. 132(5):559-565(2009)
Piscaglia, F., et al. Cell Tissue Res. 337(3):449-462(2009)